Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

Elena Kuzmanova, Marilena Spanou, Emma Leckie, Nikolai Zhelev

    Research output: Contribution to journalMeeting Abstractpeer-review


    Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.
    Original languageEnglish
    Article numbere14563
    Number of pages1
    Publication statusPublished - 5 Jul 2017
    EventWorld Biodiscovery Congress 2017 - The Sofia University, Sofia, Bulgaria
    Duration: 17 Jul 201719 Jul 2017


    • Thymidine kinase
    • Tumour-associated marker
    • Breast cancer


    Dive into the research topics of 'Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection'. Together they form a unique fingerprint.

    Cite this